Kalaris Therapeutics to Go Public Via Reverse Merger
- 11.8.2024
On November 7, 2024, Kalaris Therapeutics, a clinical-stage ophthalmology biotech company co-founded by Samsara BioCapital that is developing innovative retinal treatments, announced it had entered into a transformational reverse merger transaction with AlloVir, an allogeneic T cell immunotherapy company, pursuant to which the equityholders of Kalaris will become owners of approximately 75% of the combined company. The transaction is expected to close in the first quarter of 2025.
The WilmerHale team is led by Mark Nylen, Scott Lunin, Ciara Baker and Jason Kropp—with particularly significant contributions from Amanda Albert, Rebecca Nauta, Victoria Peluso, Frank Wang, Michaela Rosen, Shanelle Doher, Carla Gilbertson and Ben Kelsey—and comprises dozens of M&A, capital markets, public company counseling, ECVC, corporate tax, executive compensation and benefits, antitrust, IP, litigation, FDA and other experienced subject matter professionals.
